Immunome announces discovery of new coronavirus variant first in ...

On February 18, Immunome announced that it had obtained first in class-in-class antibodies capable of meso-new coronavirus variants, including the South African mutant strain B.1.351, based on its unique human memory B-cell technology platform.
the news, Immunome's shares jumped 175 per cent at one point before closing up 75 per cent.
Immunome found that "super-responders" recovering from infected SARS-CoV-2 mutants were able to produce strong immune responses to a variety of viral targets, including prickly and non-tingling proteins.
Immunome is working to develop an antibody cocktail therapy, IM-BCP-001, that binds to SARS-CoV-2 virus surface prick proteins and non-hedgehog proteins, for the prevention and treatment of COVID-19.
In the process, Immunome identified antibodies that bind to non-overlapping regions of the prickly protein (non-overlapping regions, including regions containing key mutations) and showed in active tests that it was able to mediate the expression of a fake virus specific to the South African mutant strain B.1.351.
recent literature suggests that the South African mutant strain weakens the efficacy of vaccines and some existing antibody therapies.
, chief executive of Immunome, said: "Our findings demonstrate The ability of Immunome to quickly screen extremely mutant strains of the SARS-CoV-2 virus.
we have found antibodies that bind to the conservative bits of SARS-CoV-1 and SARS-CoV-2 virus hedgehog proteins, and believe that our strategy can help fight some mutant strains.
2020, Immunome received $13.3 million from the U.S. government to support the development of its COVID program.